Gefitinib plus celecoxib induces an encouraging response rate in incurable squamous cell carcinoma of the head and neck

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1510, 2005-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacotherapy for squamous-cell carcinoma of the head and neck

By Papaspyrou Giorgos   Werner Jochen A   Dietz Andreas  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 3, 2011-02 ,pp. : 397-409

Informa Healthcare

Access to resources Recommend Favorite

Afatinib in the treatment of head and neck squamous cell carcinoma

By Ferrarotto Renata   Gold Kathryn A  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 135-143

Informa Healthcare

Access to resources Recommend Favorite

Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma

By  

Current Molecular Pharmacology, Vol. 9, Iss. 3, 2016-08 ,pp. : 226-230

Bentham Science Publishers

Access to resources Recommend Favorite

Cisplatin + capecitabine active in head, neck squamous cell carcinoma

By  

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Cetuximab: A Review of its Use in Squamous Cell Carcinoma of the Head and Neck

By Frampton James E.  

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1987-2010

Adis International

Access to resources Recommend Favorite